“A woman with a voice is by definition a strong woman” -Melinda French Gates
'Behind every great woman ... is another great woman”-Kate Hodges
ASCO Hematology & Oncology Women Physicians Group—HOWPG Women in Oncology Women In Medicine® #ASCO24 #lcsm IASLC

Only 5 Days to Go – #WCLC24 Early Bird Registration ends this Friday June 7, at midnight! Don’t miss out on fantastic networking opportunities, exceptional continued education, and hands-on workshops. Register Today and Save: bit.ly/WCLC24Reg #LCSM #IASLC50

Fantastic #oralabstract session today for #NSCLC , #mesothelioma , & #SCLC w/ my fabulous co-chair Shankar Siva at #ASCO24

⭐️BEAT-SC, BEAT-Meso ✅PFS/🛑OS
🚨ALINA ⬆️QOL > Chemo
💪ADAURA ⬇️MRD+ > PBO
‼️CM 77T 💉➕N2, ⬇️ micromets
🏠+FH 🫁 ⬆️risk in 🇹🇼 Taiwan

#LCSM IU Simon Comprehensive Cancer Center

Excellent work by Angelica D'Aiello, MD (let me also introduce her as incoming Montefiore Health System faculty!), Shayan Nazari Caris Life Sciences, Hyein Jeon, MD Haiying Cheng on a mol analysis of alternate checkpoints in NSCLC!
This project is Angelica’s baby-but as she is also a new mom-a close 2nd one👶

What a great #ASCO24 Lung Cancer poster walk. Thanks to Drs. Corey Langer Mihaela Aldea Monica Chen Enriqueta Felip for walking though their posters and all the tips and career advice!

Really important stage shift shown in Taiwan National Lung screen program. Bravo Dr PC Yang! Family hx is a key risk factor. Excited to collaborate with Allison Chang and Jill Feldman to open a clinical trial soon focused on screening in those w/ a positive family hx #ASCO24

donington discussion of CM77T; brilliant analysis describing the outcomes in N2 and specifically multistation N2; concluding resectability is about bulk and invasiveness, not number of stations. #ASCO24

Might I point out that the relevance of N2 positivity is eliminated when Nivo is in play. If you compare the green curves N2 vs non-N2 they are the same regardless of PCR status. Not so in pts treated with chemo alone. Hence, Nivolumab eliminates the TNM stage effects related to

#ASCO24 Also noting we need to improve lung cancer screening in pts currently eligible (eliminate barriers) and identify those at risk not eligible for current screening criteria.

#ASCO24 Dr. donington with an insightful discussion of CheckMate 77T update. Clear benefit of periadjuvant nivolumab - even in multi-station N2 and compelling evidence that the adjuvant nivolumab component is playing a critical role in pts with residual disease.

Dr. Pan-Chyr Yang presents the Taiwan national lung cancer early detection program for heavy smokers & non-smokers w/ family history at #ASCO24 . Noting the different biology of lung cancer in non-smokers and the need to adapt strategies to biology and populations.

Similarly to KN-671, adjuvant nivolumab in the non-pCR group seemed to add EFS benefit, specially in high-risk stage III N2 disease. Update on CM77T study. #ASCO24 #LCSM

CM77T; N2 analysis of the stage III subgroup; no difference in pCR rates or EFS between non N2 and N2; similarly for single v multistation N2; Significant difference seen favouring post op nivo after resection in N2 non pCR: #ASCO24

CheckMate-77T update

❓Is neo-adj chemoIO appropriate with N2 (poorer prog) St3

✅ EFS maintained HR 0.60 (N2) v 0.60 (non-N2)
✅ 67% w N2 had nodal downstaging
✅ N2 w/o pCR = ⬆️EFS w Niv HR 0.48

🤔 If resectable, N2 not a reason per se to avoid neo-adj chemoIO

#ASCO24 #LCSM

Outstanding presentation from A/Prof Tom John about the utility of tumour informed MRD analysis of ctDNA in the ADAURA trial. Glimpsing at the future of disease monitoring in lung cancer. Shankar Siva Misty Dawn Shields #ASCO24

Sanjay Popat BEAT-Meso
Pem/Carbo/Bev +/- Atezo in mesothelioma

❌ ITT non-signif ⬆️ OS, HR 0.84
✅ ⬆️OS non-epi, HR 0.50
✅ ⬆️OS PD-L1+, HR 0.66
✅ ⬆️OS EORTC poor prog, HR 0.60
❌ no diff ORR
❗️⬆️ AE plts, ⬇️GFR, skin
👉 no QoL difference

#ASCO24 #LCSM